RGD Reference Report - AKR1C3 overexpression may serve as a promising biomarker for prostate cancer progression. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

AKR1C3 overexpression may serve as a promising biomarker for prostate cancer progression.

Authors: Tian, Y  Zhao, L  Zhang, H  Liu, X  Zhao, L  Zhao, X  Li, Y  Li, J 
Citation: Tian Y, etal., Diagn Pathol. 2014 Feb 26;9:42. doi: 10.1186/1746-1596-9-42.
RGD ID: 10053627
Pubmed: PMID:24571686   (View Abstract at PubMed)
PMCID: PMC3939640   (View Article at PubMed Central)
DOI: DOI:10.1186/1746-1596-9-42   (Journal Full-text)

BACKGROUND: Aldo-keto reductase family 1 member C3 (AKR1C3) is a key steroidogenic enzyme that is overexpressed in prostate cancer (PCa) and is associated with the development of castration-resistant prostate cancer (CRPC). The aim of this study was to investigate the correlation between the expression level of AKR1C3 and the progression of PCa. METHODS: Sixty human prostate needle biopsy tissue specimens and ten LNCaP xenografts from intact or castrated male mice were included in the study. The relationship between the level of AKR1C3 expression by immunohistochemistry and evaluation factors for PCa progression, including prostate-specific antigen (PSA), Gleason score (GS) and age, were analyzed. RESULTS: Low immunoreactivity of AKR1C3 was detected in normal prostate epithelium, benign prostatic hyperplasia (BPH) and prostatic intraepithelial neoplasia (PIN). Positive staining was gradually increased with an elevated GS in PCa epithelium and LNCaP xenografts in mice after castration. The Spearman's r values (rs) of AKR1C3 to GS and PSA levels were 0.396 (P = 0.025) and -0.377 (P = 0.036), respectively, in PCa biopsies. The rs of AKR1C3 to age was 0.76 (P = 0.011). No statistically significant difference was found with other variables. CONCLUSION: Our study suggests that the level of AKR.1C3 expression is positively correlated with an elevated GS, indicating that AKR1C3 can serve as a promising biomarker for the progression of PCa. VIRTUAL SLIDES: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/7748245591110149.

RGD Manual Disease Annotations    Click to see Annotation Detail View
TermQualifierEvidenceWithReferenceNotesSourceOriginal Reference(s)
prostate cancer disease_progressionIEP 10053627protein:increased expression:epithelium:RGD 
prostate cancer disease_progressionISOAKR1C3 (Homo sapiens)10053627; 10053627protein:increased expression:epithelium:RGD 

Objects Annotated

Genes (Rattus norvegicus)
Akr1c3  (aldo-keto reductase family 1, member C3)

Genes (Mus musculus)
Akr1c18  (aldo-keto reductase family 1, member C18)

Genes (Homo sapiens)
AKR1C3  (aldo-keto reductase family 1 member C3)


Additional Information